Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Tourmaline Bio (NASDAQ:TRML – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Earnings & Valuation
This table compares Krystal Biotech and Tourmaline Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $290.52 million | 16.11 | $10.93 million | $2.99 | 54.15 |
| Tourmaline Bio | N/A | N/A | -$42.12 million | ($2.87) | -5.84 |
Krystal Biotech has higher revenue and earnings than Tourmaline Bio. Tourmaline Bio is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 1 | 6 | 1 | 3.00 |
| Tourmaline Bio | 0 | 0 | 6 | 0 | 3.00 |
Krystal Biotech presently has a consensus target price of $220.00, suggesting a potential upside of 35.88%. Tourmaline Bio has a consensus target price of $45.20, suggesting a potential upside of 169.69%. Given Tourmaline Bio’s higher possible upside, analysts plainly believe Tourmaline Bio is more favorable than Krystal Biotech.
Institutional & Insider Ownership
86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by insiders. Comparatively, 11.0% of Tourmaline Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Krystal Biotech and Tourmaline Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 30.69% | 11.41% | 10.40% |
| Tourmaline Bio | N/A | -20.97% | -20.56% |
Volatility and Risk
Krystal Biotech has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.
Summary
Krystal Biotech beats Tourmaline Bio on 9 of the 12 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About Tourmaline Bio
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
